ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles
Excerpt from the Press Release:
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced results from a Phase I-II clinical study at Skåne University Hospital in Lund, Sweden evaluating the ClearPoint Prism Neuro Laser Therapy System’s safety, feasibility, and efficacy. The study cohort comprised fourteen patients ages 18-80years with primary and recurrent glioblastoma and grade 4 astrocytoma, tumors which are among the most challenging to treat.
The study (NCT05296122) was led by Dr. Peter Siesjö, sponsored by CLS AB, and co-funded by the Company. Findings from the study are encouraging and demonstrated:
- Improved survival compared to matched open surgery controls
- Safe1, feasible, and reproducible workflow
- Median ablation time: 6.5 minutes.
“For patients facing limited options and an otherwise invasive procedure, these initial results suggest meaningful potential for minimally invasive laser therapy in neuro-oncology,” commented Chris Osswald, PhD, Director and Global Segment Leader for Laser Therapy. “We’re proud to be part of a solution that prioritizes precision, safety, accessibility, and patient outcomes. The fast, simple, and predictable workflow of ClearPoint Prism enables physicians to improve patient care today and may lay the groundwork for healthcare systems to build capacity and expertise in cell and gene therapy workflows that will transform tomorrow.”
The ClearPoint Prism technology will be on display at the 75th Annual Congress of Neurological Surgeons (CNS) in Los Angeles October 13-15, 2025.2
1 No device-related events or complications reported.
2 Product usage represented may not be approved or cleared in all markets.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?